Bildkälla: Stockfoto

Acarix: Glimpsing the West - Redeye

Redeye reviews its assessment of Acarix, acknowledging the clinical and regulatory progress for the CADScor device and the catalysts ahead in the form of acquired reimbursement, high-volume orders, and establishment in the US market. We hike our fair value range as our reassessment suggests a more optimistic take on the case.

Redeye reviews its assessment of Acarix, acknowledging the clinical and regulatory progress for the CADScor device and the catalysts ahead in the form of acquired reimbursement, high-volume orders, and establishment in the US market. We hike our fair value range as our reassessment suggests a more optimistic take on the case.
Börsvärldens nyhetsbrev
ANNONSER